Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Arthritis Research & Therapy
Erschienen in: Arthritis Research & Therapy 4/2002

01.06.2002 | Review

Molecular action of methotrexate in inflammatory diseases

verfasst von: Edwin SL Chan, Bruce N Cronstein

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2002

Einloggen, um Zugang zu erhalten

Abstract

Despite the recent introduction of biological response modifiers and potent new small-molecule antirheumatic drugs, the efficacy of methotrexate is nearly unsurpassed in the treatment of inflammatory arthritis. Although methotrexate was first introduced as an antiproliferative agent that inhibits the synthesis of purines and pyrimidines for the therapy of malignancies, it is now clear that many of the anti-inflammatory effects of methotrexate are mediated by adenosine. This nucleoside, acting at one or more of its receptors, is a potent endogenous anti-inflammatory mediator. In confirmation of this mechanism of action, recent studies in both animals and patients suggest that adenosine-receptor antagonists, among which is caffeine, reverse or prevent the anti-inflammatory effects of methotrexate.
Literatur
1.
Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985, 312: 818-822.PubMed
2.
Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593. 10.1056/NEJM200011303432201.PubMed
3.
Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J: Polyglutamation of methotrexate. Is methotrexate a prodrug?. J Clin Invest. 1985, 76: 907-912.PubMedPubMedCentral
4.
Baggott JE, Vaughn WH, Hudson BB: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J. 1986, 236: 193-200.PubMedPubMedCentral
5.
Allegra CJ, Drake JC, Jolivet J, Chabner BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A. 1985, 82: 4881-4885.PubMedPubMedCentral
6.
Chabner BA, Myers CE: Clinical Pharmacology of Cancer Chemotherapy. In Cancer: Principles and Practice of Oncology. Edited by: DeVita VT, Hellman S, Rosenberg SA. 1989, Philadelphia: JB Lippincott, 349-395.
7.
Ortiz Z, Shea B, Suarez-Almazor M, Moher D, Wells G, Tugwell P: Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2. 2000
8.
Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P: Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2. 2000
9.
Ravelli A, Migliavacca D, Viola S, Ruperto N, Pistorio A, Martini A: Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis. Clin Exp Rheumatol. 1999, 17: 625-627.PubMed
10.
Pincus T: Folic and folinic acid supplementation reduces methotrexate gastrointestinal side effects in rheumatoid arthritis. Clin Exp Rheumatol. 1998, 16: 667-668.PubMed
11.
Morgan SL, Baggott JE, Lee JY, Alarcon GS: Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol. 1998, 25: 441-446.PubMed
12.
Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P: The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol. 1998, 25: 36-43.PubMed
13.
Hunt PG, Rose CD, McIlvain-Simpson G, Tejani S: The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol. 1997, 24: 2230-2232.PubMed
14.
Shiroky JB: The use of folates concomitantly with low-dose pulse methotrexate. Rheum Dis Clin North Am. 1997, 23: 969-980.PubMed
15.
16.
Kavanaugh A, Kavanaugh D: Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med. 1996, 124: 73-74.PubMed
17.
Cooper BA: Folic acid and methotrexate in rheumatoid arthritis. Ann Intern Med. 1996, 124: 73-74.PubMed
18.
Dijkmans BA: Folate supplementation and methotrexate. Br J Rheumatol. 1995, 34: 1172-1174.PubMed
19.
van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, Westgeest TA, Romme TC, de Rooij DJ, Jacobs MJ, X de Boo TM, van der Wilt GJ, Severens JL, Hartman M, Krabbe PF, Dijkmans BA, Breedveld FC, van de Putte LB: Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a fortyeight week, multicenter, randomized, double-blind, placebocontrolled study. Arthritis Rheum. 2001, 44: 1515-1524. 10.1002/1529-0131(200107)44:7<1515::AID-ART273>3.0.CO;2-7.PubMed
20.
Endresen GK, Husby G: Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. An update and proposals for guidelines. Scand J Rheumatol. 2001, 30: 129-134. 10.1080/030097401300162888.PubMed
21.
Matherly LH, Czajkowski CA, Angeles SM: Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res. 1991, 51: 3420-3426.PubMed
22.
Sperling RL, Benincaso AI, Anderson RJ, Coblyn JS, Austen KF, Weinblatt ME: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum. 1992, 35: 376-384.PubMed
23.
Surette ME, Krump E, Picard S, Borgeat P: Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A[2a] receptor agonists and crucial role of autocrine activation by leukotriene B[4]. Mol Pharmacol. 1999, 56: 1055-1062.PubMed
24.
Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998, 102: 322-328.PubMedPubMedCentral
25.
Flescher E, Bowlin TL, Ballester A, Houk R, Talal N: Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis. J Clin Invest. 1989, 83: 1356-1362.PubMedPubMedCentral
26.
Flescher E, Bowlin TL, Talal N: Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids. Clin Exp Immunol. 1992, 87: 435-437.PubMedPubMedCentral
27.
Yukioka K, Wakitani S, Yukioka M, Furumitsu Y, Shichikawa K, Ochi T, Goto H, Matsui-Yuasa I, Otani S, Nishizawa Y: Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. J Rheumatol. 1992, 19: 689-692.PubMed
28.
Furumitsu Y, Yukioka K, Kojima A, Yukioka M, Shichikawa K, Ochi T, Matsui-Yuasa I, Otani S, Nishizawa Y, Morii H: Levels of urinary polyamines in patients with rheumatoid arthritis. J Rheumatol. 1993, 20: 1661-1665.PubMed
29.
Nesher G, Osborn TG, Moore TL: In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 1996, 14: 395-399.PubMed
30.
Nesher G, Moore TL: The in vitro effects of methotrexate on peripheral blood mononuclear cells. Modulation by methyl donors and spermidine. Arthritis Rheum. 1990, 33: 954-959.PubMed
31.
Cronstein BN, Eberle MA, Gruber HE, Levin RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A. 1991, 88: 2441-2445.PubMedPubMedCentral
32.
Gruber HE, Hoffer ME, McAllister DR, Laikind PK, Lane TA, Schmid-Schoenbein GW, Engler RL: Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: effects on flow, granulocytes and injury. Circulation. 1989, 80: 1400-1411.PubMed
33.
Allegra CJ, Hoang K, Yeh GC, Drake JC, Baram J: Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J Biol Chem. 1987, 262: 13520-13526.PubMed
34.
Baggott JE, Morgan SL, Koopman WJ: The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary aminoimidazole carboxamide excretion. Arthritis Rheum. 1998, 41: 1407-1410. 10.1002/1529-0131(199808)41:8<1407::AID-ART9>3.0.CO;2-H.PubMed
35.
Luhby AL, Cooperman JH: Aminoimidazole carboxamide excretion in vitamin B12 and folic acid deficiencies. Lancet. 1962, 2: 1381-1382.PubMed
36.
Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest. 1993, 92: 2675-2682.PubMedPubMedCentral
37.
Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, Carlin G, Huie MA, Cronstein BN: Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest. 1998, 101: 295-300.PubMedPubMedCentral
38.
Rosengren S, Arfors KE, Proctor KG: Potentiation of leukotriene B4-mediated inflammatory response by the adenosine antagonist, 8-phenyl theophylline. Int J Microcirc: Clin Exp. 1991, 10: 345-357.
39.
Green PG, Basbaum AI, Helms C, Levine JD: Purinergic regulation of bradykinin-induced plasma extravasation and adjuvant-induced arthritis in the rat. Proc Natl Acad Sci U S A. 1991, 88: 4162-4165.PubMedPubMedCentral
40.
Szabo C, Scott GS, Virag L, Egnaczyk G, Salzman AL, Shanley TP, Hasko G: Suppression of macrophage inflammatory protein [MIP]-1 alpha production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol. 1998, 125: 379-387.PubMedPubMedCentral
41.
Silke C, Murphy MS, Buckley T, Busteed S, Molloy MG, Phelan M: The effects of caffeine ingestion on the efficacy of methotrexate. Rheumatology [Oxford]. 2001, 40 (suppl1): S34-
42.
Halliwell B, Hoult JR, Blake DR: Oxidants, inflammation, and anti-inflammatory drugs. FASEB J. 1988, 2: 2867-2873.PubMed
43.
Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R: Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med. 1983, 158: 1160-1177.PubMed
44.
Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R: A new physiological function for adenosine: regulation of superoxide anion production. Trans Assoc Am Physicians. 1983, 96: 384-391.PubMed
45.
Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G, Hirschhorn R: Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol. 1985, 135: 1366-1371.PubMed
46.
Cronstein BN, Haines KA, Kolasinski SL, Reibman J: Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil. Blood. 1992, 80: 1052-1057.PubMed
47.
Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J: Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A[2A] receptor agonists. Br J Pharmacol. 1992, 132: 1017-1026.
48.
Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R: Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986, 78: 760-770.PubMedPubMedCentral
49.
Cronstein BN, Levin RI, Philips MR, Hirschhorn R, Abramson SB, Weissmann G: Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992, 148: 2201-2206.PubMed
50.
Wakai A, Wang JH, Winter DC, Street JT, O'Sullivan RG, Redmond HP: Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation. Shock. 2001, 15: 297-301.PubMed
51.
Salmon JE, Cronstein BN: Fcgamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol. 1990, 145: 2235-2240.PubMed
52.
Ottonello L, Amelotti M, Barbera P, Dapino P, Mancini M, Tortolina G, Dallegri F: Chemoattractant-induced release of elastase by tumor necrosis factor- primed human neutrophils: auto-regulation by endogenous adenosine. Inflamm Res. 1999, 48: 637-642. 10.1007/s000110050515.PubMed
53.
Firestein GS, Bullough DA, Erion MD, Jimenez R, Ramirez-Wein-house M, Barankiewicz J, Smith CW, Gruber E, Mullane KM: Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor: the role of selectins. J Immunol. 1995, 154: 326-334.PubMed
54.
Wollner A, Wollner S, Smith JB: Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 [CD11b/CD18] expression on FMLP-stimulated neutrophils. Am J Resp Cell Mol Biol. 1993, 9: 179-185.
55.
Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR: Macrophages in rheumatoid arthritis. Arthritis Res. 2000, 2: 189-202. 10.1186/ar86.PubMedPubMedCentral
56.
Salmon JE, Brogle N, Brownlie C, Edberg JC, Kimberly RP, Chen BX, Erlanger BF: Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J Immunol. 1993, 151: 2775-2785.PubMed
57.
Leonard EJ, Shenai A, Skeel A: Dynamics of chemotactic peptide-induced superoxide generation by human monocytes. Inflammation. 1987, 11: 229-240.PubMed
58.
Merrill JT, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, Lahita J, Salmon RG, Cronstein BN: Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 1997, 40: 1308-1315.PubMed
59.
Merrill TJ, Shen C, Schreibman D, Coffey D, Zakharenko O, Fisher R, Lahita RG, Salmon J, Cronstein BN: Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes, a mechanism for methotrexate-induced nodulosis in rheumatoid arthritis. Arthritis Rheum. 1995, 38 (Suppl): S157-
60.
Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S: Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol. 1997, 45: 132-139. 10.1046/j.1365-3083.1997.d01-377.x.PubMed
61.
Prabhakar U, Brooks DP, Lipshlitz D, Esser KM: Inhibition of LPS-induced TNF alpha production in human monocytes by adenosine [A2] receptor selective agonists. Int J Pharmacol. 1995, 17: 221-224. 10.1016/0192-0561(94)00096-7.
62.
Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS: Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol. 1996, 156: 3435-3442.PubMed
63.
McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, De M, Borcherding DR, Edwards CK: Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol. 1996, 310: 209-216. 10.1016/0014-2999(96)00272-5.PubMed
64.
Bouma MG, Stad RK, van den Wildenberg FA, Buurman WA: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol. 1994, 153: 4159-4168.PubMed
65.
Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES: Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol. 1996, 157: 4634-4640.PubMed
66.
Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN: Inflammatory cytokines regulate function and expression of adenosine A2A receptors in human monocytoid THP-1 cells. J Immunol. 2001, 167: 4026-4032.PubMed
67.
Xaus J, Mirabet M, Lloberas J, Soler C, Lluis C, Franco R, Celada A: IFN-gamma up-regulates the A2B adenosine receptor expression in macrophages: a mechanism of macrophage deactivation. J Immunol. 1999, 162: 3607-3614.PubMed
68.
Lennon PF, Taylor CT, Stahl GL, Colgan SP: Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med. 1998, 188: 1433-1443. 10.1084/jem.188.8.1433.PubMedPubMedCentral
69.
Richard LF, Dahms TE, Webster RO: Adenosine prevents permeability increase in oxidant-injured endothelial monolayers. Am J Physiol. 1998, 274: H35-H42.PubMed
70.
Bouma MG, van den Wildenberg FAJM, Buurman WA: Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol. 1996, 39: C522-C529.
71.
Grant MB, Tarnuzzer RW, Caballero S, Ozeck MJ, Davis MI, Spoerri PE, Feoktistov I, Biaggioni I, Shryock JC, Belardinelli L: Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res. 1999, 85: 699-706.PubMed
72.
Ethier MF, Chander V, Dobson JG: Adenosine stimulates proliferation of human endothelial cells in culture. Am J Physiol. 1993, 265: H131-H138.PubMed
73.
Sexl V, Mancusi G, Baumgartner-Parzer S, Schutz W, Freissmuth M: Stimulation of human umbilical vein endothelial cell proliferation by A2-adenosine and beta 2-adrenoceptors. Br J Pharmacol. 1995, 114: 1577-1586.PubMedPubMedCentral
74.
Harrington EO, Smeglin A, Newton J, Ballard G, Rounds S: Protein tyrosine phosphatase-dependent proteolysis of focal adhesion complexes in endothelial cell apoptosis. Am J Physiol Lung Cell Mol Physiol. 2001, 280: L342-L353.PubMed
75.
Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ: Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990, 33: 1156-1161.PubMed
76.
Spadaro A, Riccieri V, Sili Scavalli A, Taccari E, Zoppini A: One year treatment with low dose methotrexate in rheumatoid arthritis: effect on class specific rheumatoid factors. Clin Rheumatol. 1993, 12: 357-360.PubMed
77.
Olsen NJ, Teal GP, Brooks RH: IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions. 1991, 34: 169-171.PubMed
78.
Moore S, Ruska K, Peters L, Olsen NJ: Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis. Immunol Invest. 1994, 23: 355-365.PubMed
79.
Olsen NJ, Callahan LF, Pincus T: Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum. 1987, 30: 481-488.PubMed
80.
Olsen NJ, Murray LM: Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum. 1989, 32: 378-385.PubMed
81.
Wascher TC, Hermann J, Brezinschek HP, Brezinschek R, Wilders-Truschnig M, Rainer F, Krejs GJ: Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Invest. 1994, 72: 535-540.
82.
Nakazawa F, Matsuno H, Yudoh K, Katayama R, Sawai T, Uzuki M, Kimura T: Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. J Rheumatol. 2001, 28: 1800-1808.PubMed
83.
Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS: Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988, 31: 167-175.PubMed
84.
Mirabet M, Herrera C, Cordero OJ, Mallol J, Lluis C, Franco R: Expression of A2B adenosine receptors in human lymphocytes: their role in T cell activation. J Cell Sci. 1999, 112: 491-502.PubMed
85.
Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C: Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol. 1996, 156: 1349-1355.PubMed
86.
van den Berg WB: Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res. 2001, 3: 18-26. 10.1186/ar136.PubMedPubMedCentral
87.
DiMartino MJ, Johnson WJ, Votta B, Hanna N: Effect of antiarthritic drugs on the enhanced interleukin-1 [IL-1] production by macrophages from adjuvant-induced arthritic [AA] rats. Agents Actions. 1987, 21: 348-350.PubMed
88.
Novaes GS, Mello SB, Laurindo IM, Cossermelli W: Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits. J Rheumatol. 1996, 23: 2092-2097.PubMed
89.
Chang DM, Weinblatt ME, Schur PH: The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol. 1992, 19: 1678-1682.PubMed
90.
Segal R, Mozes E, Yaron M, Tartakovsky B: The effects of methotrexate on the production and activity of Il-1. Arth Rheum. 1989, 32: 370-377.
91.
Chang DM, Baptiste P, Schur PH: The effect of antirheumatic drugs on interleukin 1 [IL-1] activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol. 1990, 17: 1148-1157.PubMed
92.
Brody M, Bohm I, Bauer R: Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem. 1993, 31: 667-674.PubMed
93.
Majumdar S, Aggarwal BB: Methotrexate suppresses Nf-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation. J Immunol. 2001, 167: 2911-2920.PubMed
94.
Eigler A, Matschke V, Hartmann G, Erhardt S, Boyle D, Firestein GS, Endres S: Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitor. J Leukoc Biol. 2000, 68: 97-103.PubMed
95.
Becker C, Barbulescu K, Hildner K, Meyer zum Buschenfelde KH, Neurath MF: Activation and methotrexate-mediated suppression of the TNF alpha promoter in T cells and macrophages. Ann N Y Acad Sci. 1998, 859: 311-314.PubMed
96.
Neurath MF, Hildner K, Becker C, Schlaak JF, Barbulescu K, Germann T, Schmitt E, Schirmacher P, Haralambous S, Pasparakis M, Meyer Zum Buschenfelde KH, Kollias G, Marker-Hermann E: Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis [CIA]: a mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol. 1999, 115: 42-55. 10.1046/j.1365-2249.1999.00753.x.PubMedPubMedCentral
97.
Hildner K, Finotto S, Becker C, Schlaak J, Schirmacher P, Galle PR, Marker-Hermann E, Neurath MF: Tumour necrosis factor [TNF] production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin Exp Immunol. 1999, 118: 137-146. 10.1046/j.1365-2249.1999.01022.x.PubMedPubMedCentral
98.
Rudwaleit M, Yin Z, Siegert S, Grolms M, Radbruch A, Braun J, Sieper J: Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor alpha, increase of interleukin 10, and predicted by the initial concentration of interleukin 4. Ann Rheum Dis. 2000, 59: 311-314. 10.1136/ard.59.4.311.PubMedPubMedCentral
99.
Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK, Seok JH, Lee JH, Hur GM: Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology. 2000, 47: 35-44. 10.1016/S0162-3109(99)00185-X.PubMed
100.
Spadaro A, Taccari E, Riccieri V, Sensi F, Sili Scavalli A, Zoppini A: Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis. Rev Rhum Engl Ed. 1997, 64: 89-94.PubMed
101.
Constantin A, Loubet-Lescoulie P, Lambert N, Yassine-Diab B, Abbal M, Mazieres B, de Preval C, Cantagrel A: Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 1998, 41: 48-57. 10.1002/1529-0131(199801)41:1<48::AID-ART7>3.3.CO;2-B.PubMed
Metadaten
Titel
Molecular action of methotrexate in inflammatory diseases
verfasst von
Edwin SL Chan
Bruce N Cronstein
Publikationsdatum
01.06.2002
Verlag
BioMed Central
Erschienen in
Arthritis Research & Therapy / Ausgabe 4/2002
Elektronische ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar419

Weitere Artikel der Ausgabe 4/2002

Arthritis Research & Therapy 4/2002 Zur Ausgabe

Review

Use of soluble MHC class II/peptide multimers to detect antigen-specific T cells in human disease

Research article

Fragmentation of Golgi complex and Golgi autoantigens during apoptosis and necrosis

Commentary

The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases

Meeting report

22nd European Workshop for Rheumatology Research, Leiden, The Netherlands, 28 February–3 March 2002

Review

The vasculature and its role in the damaged and healing tendon

Commentary

The role of statins as potential targets for bone formation

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

10.05.2024 Periphere arterielle Verschlusskrankheit Nachrichten

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise